Research Alert: CFRA Keeps Buy Rating On Shares Of Danaher Corporation
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We maintain our target at $258, 27.6x our 2027 EPS estimate, a discount to DHR's five-year historical forward P/E average. We slightly raise our 2026 EPS view to $8.57 from $8.53 to reflect the Q1 beat. We keep our 2027 EPS forecast at $9.35. In our view, Danaher's Q1 results demonstrated solid execution, with adjusted EPS of $2.06 beating consensus by 6%. Bioprocessing showed encouraging momentum with 7% core growth and equipment orders up 30% Y/Y, the first positive order growth in nearly two years, which we see as a positive leading indicator. While respiratory sales revenue were lighter than expected, strength in Life Sciences and Bioprocessing offset this headwind. China trends improved across Biotech and Life Sciences segments. The large $9.9 billion pending Masimo acquisition announced in February remains on track for a 2H 2026 close, and should significantly expand DHR's diagnostics and medical technology portfolio. We expect the deal to be EPS accretive in year one.